Related Experiment Video
Updated: Jul 2, 2026
09:01
Integrate Imaging Flow Cytometry and Transcriptomic Profiling to Evaluate Altered Endocytic CD1d Trafficking
Published on: October 29, 2018
Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine
Pi-Hui Liang1, Masakazu Imamura, Xiangming Li
1The Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang Dist., Taipei, Taiwan 11529.
Journal of the American Chemical Society
|August 21, 2008
Summary
This study shows that modified alpha-galactosyl ceramide (alpha-GalCer) ligands bind strongly to CD1d, enhancing T(H)1 immune responses. Tighter binding correlates with increased IFN-gamma, suggesting a pathway bias.
Area of Science:
- Immunology
- Biochemistry
- Molecular Biology
Background:
- CD1d protein presents glycolipids to T cells, influencing immune responses.
- Understanding CD1d-glycolipid interactions is crucial for immune modulation.
Purpose of the Study:
- To investigate the binding affinity of various glycolipid ligands to CD1d.
- To determine how binding strength affects NKT cell cytokine release.
Main Methods:
- Glycolipid ligands were immobilized on a microarray surface for CD1d binding assays.
- Surface plasmon resonance and competition assays were used to quantify binding constants (Kd and Ki).
- Interferon-gamma (IFN-γ) and Interleukin-4 (IL-4) release from NKT cells were measured.
Main Results:
- A modified alpha-galactosyl ceramide (alpha-GalCer) derivative exhibited significantly higher binding affinity to CD1d compared to native alpha-GalCer.
- The binding affinity of glycolipids to CD1d strongly correlated with IFN-γ production by NKT cells.
- A poor correlation was observed between binding affinity and IL-4 secretion, indicating a T(H)1 bias.
Conclusions:
- Enhanced binding affinity of glycolipids to CD1d can preferentially activate T(H)1 immune responses.
- Modified alpha-GalCer analogues represent potent tools for modulating NKT cell activity.
- These findings have implications for the development of targeted immunotherapies.
